Search results
Showing 736 to 750 of 1877 results for do not dos
Radiofrequency denervation for osteoarthritic knee pain (HTG686)
Evidence-based recommendations on radiofrequency denervation for osteoarthritic knee pain. This involves applying heat (radiofrequency) energy to damage the nerves (denervation) that are causing pain in the knee.
View recommendations for HTG686Show all sections
Endovenous mechanochemical ablation for varicose veins (HTG414)
Evidence-based recommendations on endovenous mechanochemical ablation for varicose veins. This involves using a rotating wire and chemical to close the varicose vein.
Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) (HTG122)
Evidence-based recommendations on deep brain stimulation for tremor and dystonia (excluding Parkinson's disease). This involves planting electrodes in the brain and generating electrical currents to help control the tremor or dystonia.
View recommendations for HTG122Show all sections
Sections for HTG122
Percutaneous radiofrequency ablation for atrial fibrillation (HTG110)
Evidence-based recommendations on percutaneous radiofrequency ablation for atrial fibrillation. This involves inserting a catheter into the heart that produces heat to damage the nerves in the area with the abnormal elecritcal impulses.
View recommendations for HTG110Show all sections
Sections for HTG110
Evidence-based recommendations on intranasal phototherapy for allergic rhinitis in adults. This involves using light to reduce inflammation inside the nose.
View recommendations for HTG473Show all sections
Endobronchial ultrasound-guided transbronchial biopsy for peripheral lung lesions (HTG214)
Evidence-based recommendations on endobronchial ultrasound-guided transbronchial biopsy for peripheral lung lesions. This involves inserting an ultrasound probe via the patient’s nose or mouth into the lungs to obtain images as a guide for taking samples of the lesions.
View recommendations for HTG214Show all sections
Sections for HTG214
Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults.
This quality standard covers decision making in people aged 16 and over, using health and social care services who may lack capacity to make their own decisions (now or in the future). It aims to support implementation of the aims and principles of the Mental Capacity Act 2005 and relevant Codes of Practice. It is not a substitute for these.
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)
Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell lymphoma in adults.
This quality standard covers care for adults (aged 18 and over) who are malnourished or at risk of malnutrition in hospital or in the community. It includes identifying people at risk of malnutrition and providing nutrition support, including dietary changes and artificial nutrition support given through feeding tubes (enteral nutrition) or directly into a vein (parenteral nutrition). It describes high-quality care in priority areas for improvement.
View quality statements for QS24Show all sections
Sections for QS24
- Quality statements
- Quality statement 1: Screening for the risk of malnutrition
- Quality statement 2: Treatment
- Quality statement 3: Documentation and communication of results and nutrition support goals
- Quality statement 4: Self-management of artificial nutrition support
- Quality statement 5: Review
- About this quality standard
This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
Artificial intelligence (AI) technologies to help detect or characterise colorectal polyps (HTG773)
Evidence-based recommendations on artificial intelligence technologies to help detect or characterise colorectal polyps.
Our experts can offer advice and support in contextualising our guidelines, or helping you adapt our content to your country or local context.
Our quality standards set out priority areas for quality improvement in health, public health and social care.
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)
Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.
Show all sections